Recent BioUtah News & Events

PolarityTE provided a business update and reported financial results for the quarterly period ended September 30, 2022.

PolarityTE confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.

Clene announced that it has entered into a securities purchase agreement with certain existing stockholders.

The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results […]

$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal products.

Myriad Genetics announced financial results for its third quarter ended September 30, 2022 and provided an update on business performance.

Renalytix announced its full year results for the twelve months ended 30 June 2022.

Merit Medical Systems announced revenue of $287.2 million for the quarter ended September 30, 2022.

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2022

Renalytix announced that the Federal Medicare Administrative Contractor (MAC) National Government Services (NGS) has initiated payment of claims for KidneyIntelX testing for patients with Medicare coverage.

The Women’s Tech Council announced eight award recipients from its twenty one finalists.

Geneial announces a multimillion dollar, non-dilutive award from the National Human Genome Research Institute to fund the development of their secure, decentralized platform.

SINTX announces the receipt of a Phase II award of $1.1M, issued by the U.S. Department of Energy (DOE) to develop, design and characterize 3D-printed alumina ceramic heat exchangers for heating, ventilation, and air conditioning systems (HVAC).

SINTX announced a Phase I grant of $275k awarded by the National Institutes of Health (NIH) to develop and test an antimicrobial trauma device.

CNS Clinical Research Veteran Brings Extensive Expertise in Global Project Management & Operations

Foldax announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday.

Four presentations, including first clinical utility findings from multi-year real world evidence results from a major healthcare system underscore value of KidneyIntelX™ platform in improving cost economics for Medicare population.

Senator Mike Lee (R-UT) has introduced the “Protecting Drug Innovation Act” which would roll back Medicare’s authority to set drug prices through a new punitive negotiation program. This government price-setting policy was a key component of the Democrats’ “Inflation Reduction Act” (IRA). The non-partisan Congressional Budget Office has estimated that the IRA’s drug pricing provisions […]

Senator Mike Lee (R-UT) and a group of like-minded colleagues are preparing to send a letter to CMS Administration Chiquita Brooks-LaSure urging the agency to issue a proposed rule by year’s end to provide accelerated Medicare coverage for emerging medical technologies. Medicare patients should have timely access to innovative and beneficial care, which can change […]

 Attendance at premiere medical technology convention to spur partnership, growth opportunities. SALT LAKE CITY, October 10, 2022 /PRNewswire/ – EVŌQ Bio (an EVŌQ Nano company), a nano-platform technology company, is pleased to announce their attendance at the MedTech Conference 2022 in Boston, Massachusetts October 24-26, 2022. The MedTech Conference is the premiere venue for executives […]

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT) (the “Company”) announces that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for a new prescription monitoring device for infants. The Company’s device, which uses pulse oximetry technology, is intended to be prescribed by physicians for assisting with the in-home monitoring […]

Woods Cross, UT (October 6, 2022) – Phoenix PharmaLabs, Inc. (https://phoenixpharmalabs.com), a private company developing potent, non-addictive treatments for pain and addiction, today announced the receipt of an $8.7 million grant from the National Institute on Drug Abuse (NIDA). The primary focus of the grant is to study the company’s lead compound, PPL-138, for the […]

Xenter unveiled XenFI™, the first product in its wireless “Technology in Medicine” ecosystem.

Completion of Trial is a Sign of Things to Come for Novel Embolic Agent